PLX (Protalix BioTherapeutics, Inc. Common Stock)
Insider Trading Activity
Every open-market purchase and sale reported by PLX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-23 | Dror Bashan | PRESIDENT AND CEO | Buy | — | — |
| 2025-11-19 | Amos Bar-Shalev | Director | Sell | — | — |
| 2025-09-04 | Gwen A Melincoff | Director | A | — | — |
| 2025-09-04 | Christian Elze | Director | A | — | — |
| 2025-09-04 | Zvi Shmuel Ben | Director | A | — | — |
| 2025-09-04 | Aharon Schwartz | Director | A | — | — |
| 2025-09-04 | Amos Bar-Shalev | Director | A | — | — |
| 2025-09-04 | Pol F Boudes | Director | A | — | — |
| 2025-09-04 | Dror Bashan | PRESIDENT AND CEO | A | — | — |
| 2025-09-04 | Yaron Naos | Sr. VP, Operations | A | — | — |
| 2025-09-04 | Eliot Forster | Director | A | — | — |
| 2025-08-12 | Aharon Schwartz | Director | Buy | — | — |
| 2024-11-05 | Eyal Rubin | Sr. VP and CFO | A | — | — |
| 2024-09-24 | Yaron Naos | Sr. VP, Operations | A | — | — |
| 2024-09-24 | Eyal Rubin | Sr. VP and CFO | A | — | — |
| 2024-04-03 | Dror Bashan | PRESIDENT AND CEO | A | — | — |
| 2023-10-20 | Dror Bashan | PRESIDENT AND CEO | Buy | — | — |
| 2023-10-03 | Zvi Shmuel Ben | Director | A | — | — |
| 2023-10-03 | Pol F Boudes | Director | A | — | — |
| 2023-10-03 | Aharon Schwartz | Director | A | — | — |
| 2023-10-03 | Amos Bar-Shalev | Director | A | — | — |
| 2023-10-03 | Gwen A Melincoff | Director | A | — | — |
| 2023-09-15 | Eliot Forster | Director | A | — | — |
| 2023-08-17 | Yaron Naos | Sr. VP, Operations | A | — | — |
| 2023-08-17 | Dror Bashan | President and CEO | A | — | — |
| 2023-08-17 | Eyal Rubin | Sr. VP and CFO | A | — | — |
| 2023-08-17 | Yael Hayon | VP, Research & Development | A | — | — |
| 2023-01-05 | Aharon Schwartz | Director | Buy | — | — |
| 2022-09-09 | Pol F Boudes | Director | A | — | — |
| 2022-09-09 | Eyal Rubin | Sr. VP and CFO | A | — | — |
| 2022-09-09 | Dror Bashan | President and CEO | A | — | — |
| 2022-09-09 | Zvi Shmuel Ben | Director | A | — | — |
| 2022-09-09 | Yael Hayon | VP, Research & Development | A | — | — |
| 2022-09-09 | Amos Bar-Shalev | Director | A | — | — |
| 2022-09-09 | Gwen A Melincoff | Director | A | — | — |
| 2022-09-09 | Yaron Naos | Sr. VP, Operations | A | — | — |
| 2022-09-09 | Zeev Bronfeld | Director | A | — | — |
| 2022-09-09 | Aharon Schwartz | Director | A | — | — |
| 2022-07-05 | Zvi Shmuel Ben | Director | A | — | — |
| 2022-04-13 | Dror Bashan | President and CEO | Buy | — | — |
| 2022-02-28 | Eyal Rubin | Sr. VP and CFO | A | — | — |
| 2022-02-28 | Dror Bashan | President and CEO | A | — | — |
| 2021-06-03 | Dexcel Pharma Technologies Ltd. | 10%+ Owner | Sell | — | — |
| 2020-08-14 | Dror Bashan | President and CEO | A | — | — |
| 2020-08-14 | Eyal Rubin | Sr. VP and CFO | A | — | — |
| 2020-08-13 | Dror Bashan | President and CEO | A | — | — |
| 2020-08-13 | Eyal Rubin | Sr. VP and CFO | A | — | — |
| 2020-08-13 | Yaron Naos | Sr. VP, Operations | A | — | — |
| 2020-07-08 | Yael Hayon | VP, Research & Development | A | — | — |
| 2020-06-08 | Einat Brill Almon | SVP, Chief Development Officer | A | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 4,494,820 | — |
| — | PRESIDENT AND CEO | 2,532,934 | — |
| — | 10%+ Owner | 1,077,500 | — |
| — | 10%+ Owner | 794,408 | — |
| — | 10%+ Owner | 770,419 | — |
| — | Sr. VP and CFO | 660,909 | — |
| — | Director | 535,422 | — |
| — | Director | 492,771 | — |
| — | Director | 310,500 | — |
| — | Sr. VP, Operations | 232,929 | — |
| — | Director | 216,248 | — |
| — | 10%+ Owner | 150,995 | — |
| — | Executive VP, R&D | 79,592 | — |
| — | President & CEO | 41,800 | — |
| — | VP, Research & Development | 35,115 | — |
| — | VP, Chief Financial Officer | 19,500 | — |
| — | SVP, Chief Development Officer | 18,500 | — |
| — | Chief Operating Officer | 10,200 | — |
| — | Director | 7,540 | — |
| — | Director | 7,500 | — |
| — | Director | 7,500 | — |
| — | Director | 7,500 | — |
| — | Director | 7,500 | — |
| — | Director | 7,500 | — |
| — | President & CEO | 5,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the PLX quote page; the site-wide leaderboard is on the insider transactions hub.